Will you Be Attending “A Shifting Landscape: Treatment of MCL” At ASH?

Photo Credit: Monkeybusinessimages

A Shifting Landscape: Treatment of MCL

Mantle Cell Lymphoma is a rare subtype of B-cell non-Hodgkin Lymphoma characterized by disease heterogeneity.  The approach to treating patients diagnosed with mantle cell lymphoma has evolved over time with therapeutics including high dose cytarabine containing regimens prior to autologous stem cell consolidation, rituximab maintenance and the oral Bruton’s tyrosine kinase inhibitors for relapsed/refractory disease.  It is recognized that not all patients benefit from these approaches.  This educational session will explore the evolving treatment landscape in mantle cell lymphoma including identification and treatment of patients with high-risk disease, the role of autologous stem cell transplant consolidation in the era of novel therapies and the current and future incorporation of T-cell engaging therapies in the treatment landscape.

Dr. Kami Maddocks will define high-risk features in Mantle Cell Lymphoma associated with inferior prognosis to standard treatment approaches. Clinical trials incorporating Bruton’s tyrosine kinase inhibitors into initial therapy will be discussed. The role of targeted and immunotherapy combinations in a “chemotherapy-free” approach will be presented.

Dr. Martin Dreyling will discuss the role of autologous stem cell transplantation and additional consolidation/maintenance therapies in first line treatment. Clinical trials incorporating Bruton’s tyrosine kinase inhibitors into initial therapy will be mentioned. Differential treatment strategies according to clinically applicable biological risk factors will be suggested.

Dr. Lia Palomba will review T-cell engaging therapies in relapsed or refractory Mantle Cell Lymphoma, including CAR T-cells and bispecific antibodies. She will review available data on the outcome of these therapies in the general MCL population and in high-risk subgroups.

Chair:

Kami J. Maddocks, MD
The Ohio State University
Columbus, OH

Speakers:

Kami J. Maddocks, MD
The Ohio State University
Columbus, OH
Your Chemo is No Good Here: Management of High-Risk MCL

Martin Dreyling, MD
LMU University Hosptial München
Munich, Germany
To Consolidate or Not to Consolidate: The Role of Autologous Stem Cell Transplantation in MCL

Maria Lia Palomba, MD
Memorial Sloan Kettering
New York, NY
T-cell–based Therapies for Treating Relapsed or Refractory Mantle Cell Lymphoma